Press & Blog

February 11, 2022

Today, we are excited to announce that our Co-Founder and Board Member, Jean Case, has been elected chairman of the Board of Trustees of the National Geographic Society.  We could not be more proud of her as she steps into this role with such an iconic organization.

Jean joins a successful line of stewards who have guided National Geographic to great heights over the course of its rich 128-year history. From her co-founding of ABC2 to her pioneering efforts at the Case Foundation and AOL, Jean has worked tirelessly to create opportunities that enrich people’s lives and...

January 8, 2022

LA JOLLA—Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just over a year.

But scientists at the Salk Institute have discovered a key to how these tumor cells proliferate so quickly —and ways to turn this engine of tumor growth into a target for cancer treatment.

“This is a disease for which there has been practically no improvement in...

November 21, 2021

Celldex Therapeutics is developing Rintega, a treatment for glioblastoma, and results presented at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) showed a significant increase in long-term overall survival for patients who participated in Rintega's phase 2 trials.  

ABC2 funded this research in the early stages.  "This is the vaccine developed by Drs. John Sampson and Duane Mitchell at Duke for the 30% of patients with an EGFRvIII mutation in their brain tumors ," said Max Wallace, CEO of ABC2. "Certainly not a cure, but positive...

Press Releases
November 12, 2021
A Groundbreaking Global Alliance Forms to Find Effective Response to the Deadliest Human Brain Tumor: GBM AGILE (An Adaptive, Global, Innovative Learning Environment) to Implement Unprecedented International Clinical Trial
November 12, 2021
Guest blogger Dr. Anna Barker announces the design and plan for the GBM AGILE trial. This trial represents the first global initiative created by a groundbreaking global coalition of some of the world’s leading GBM neuro-surgeons, neuro-oncologists, and clinical investigators and researchers. The GBM AGILE trial will be a learning system, where a patient’s individualized response to specific treatments will inform the ongoing direction of the trial.